Loading people...
Carl Kilander is a Partner at HealthCap based in Stockholm, Sweden, focusing on early-stage biotechnology and healthcare venture capital investments. Before entering venture capital, he worked as a physician and surgical researcher, earning an MD and a PhD in Medical Science from the Karolinska Institutet. At HealthCap:a firm that has raised eight funds and backed over 127 companies since 1996:he specializes in therapeutics targeting unmet medical needs. He serves as a board director for several clinical-stage startups, including Hemab Therapeutics, which closed a $135 million Series B financing round in February 2023. He also holds a board seat at NMD Pharma following its €75 million Series B funding round in November 2023, alongside his involvement with Synendos Therapeutics. Kilander leverages his clinical and academic medical background to build and scale transformative European life sciences companies.
Carl Kilander serves as a distinguished Partner at HealthCap, a leading European venture capital firm exclusively dedicated to the life sciences sector. At HealthCap, Mr. Kilander plays a pivotal role in shaping the future of healthcare by identifying, evaluating, and investing in innovative companies poised for significant impact. His expertise spans a broad spectrum of life science domains, including cutting-edge biotechnology, novel pharmaceuticals, advanced medical technology, and digital health solutions. He is particularly focused on early-stage and growth-stage companies that are developing transformative therapies and diagnostics to address unmet medical needs.
Before joining HealthCap, Carl Kilander built a robust career foundation within the life science industry, gaining invaluable experience that informs his investment strategies today. While specific details of his early career are not publicly detailed, a Partner at HealthCap typically brings a strong background in scientific research, clinical development, business development within pharmaceutical or biotech companies, or extensive financial expertise in healthcare. This diverse background equips him with a deep understanding of both the scientific intricacies and the commercial realities of bringing new medical innovations to market. His strategic insights are crucial in guiding portfolio companies through critical development milestones, regulatory hurdles, and market entry.
As part of the HealthCap team, Carl Kilander contributes to a legacy of successful investments that have brought numerous life-saving and life-improving products to patients worldwide. HealthCap's investment philosophy emphasizes rigorous due diligence, active portfolio management, and a long-term commitment to its ventures. While specific individual investments attributed solely to Mr. Kilander are not always publicly disclosed, his involvement ensures that HealthCap continues to back companies with strong scientific foundations, clear clinical pathways, and significant market potential. His work helps to foster an ecosystem where scientific breakthroughs can translate into tangible healthcare solutions, driving both innovation and value creation within the global life science landscape. Through his leadership and strategic vision, Carl Kilander remains a key figure in advancing medical innovation through venture capital.
Carl Kilander is a Partner at HealthCap, a prominent European venture capital firm specializing in life science investments. He is a key figure in identifying and supporting innovative companies in biotechnology, pharmaceuticals, and medical technology.
Carl Kilander primarily invests in life science companies through HealthCap. His focus areas include biotechnology, pharmaceuticals, medical technology, and digital health solutions, particularly those developing transformative therapies and diagnostics.
Carl Kilander works as a Partner at HealthCap, a leading European venture capital firm dedicated to the life sciences sector.
